Veracyte faces shareholder inquiry following share price decline
Legal firm SueWallSt has initiated an investigation into Veracyte after the company's stock dropped following a downward outlook for its Decipher Prostate product line.
Veracyte stock fell significantly after the company disclosed its third-quarter 2026 financial results on November 4. Although the diagnostic firm reported $151.8 million in quarterly revenue and announced a $100 million share repurchase program, investors reacted negatively to management's revised growth projections for the Decipher Prostate test.
The law firm SueWallSt is now investigating whether Veracyte or its executives violated federal securities laws. The inquiry seeks to determine if the company provided misleading information or failed to disclose material risks regarding the performance and market outlook of its prostate cancer diagnostic portfolio.
The decline in share price reflects broader market sensitivity to growth projections in the medical diagnostic sector. Veracyte shareholders are currently reviewing potential claims related to the information released during the early November reporting period.